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rials, labour and surgical procedures) and are dependent
on TTH. RESULTS: After 18,000 iterations the average
TTH (cost) fell from 25.9 (€2136) to 22.0 weeks (€1987)
for small ulcers (<10cm2) and from 39.0 (€7047) to 33.0
weeks (€6362) for large ulcers (>=10cm2) when UK-97-
0005 Device was added. Corresponding coefﬁcients of
variation ranged between 99% and 125% for TTH and
86% and 120% for costs. The main cost driver was
labour costs (75% and 84% for small and large ulcers,
respectively). The remaining costs were split equally on
materials and surgical procedures. Break-even was
reached at a relative efﬁcacy of UK-97-0005 Device of
7%. On the basis of an average prevalence of VLU of
0.2% in Sweden, the total cost of treating VLU-patients
with UK-97-0005 Device was estimated to €59.7 million.
CONCLUSION: At a relative efﬁcacy above 7%, UK-97-
0005 Device was shown to be a dominant alternative
compared to conventional treatment of VLU in Sweden.
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OBJECTIVES: Sirolimus-eluting coronary stents (SES)
are able to strikingly reduce instent restenoses as com-
pared with conventional bare metal stents (BMS) and
entered the European market in April 2002. We thus
aimed at estimating SES expected economic impact on the
national health-care system (NHS) in Italy. METHODS:
A decision model was developed in Excel and four revas-
cularization strategies were compared (PTCA, BMS, SES,
CABG) in a population of patients with new stenoses in
native coronary arteries. Four subgroups of lesions were
studied, either single-vessel (small vessel, long lesion, 
Benestent-like lesion) or multivessel. Diabetics were sep-
arately analyzed. Incremental cost per revascularization
avoided and cost per event-free year gained were calcu-
lated at a 1 and 5-year time frame and 3% discount rate
was applied to both costs and efﬁcacy. Input data were
from the published trials: BARI, BENESTENT I&II,
ARTS, RAVEL. A survey of 3298 patients in 3 cathlabs
captured the real-life casemix and current practice and
allowed to customize the model. Italian NHS charges
were used to estimate the ﬁnancial impact. RESULTS: In
the ﬁrst year after revascularization, as compared with
BMS, SES averted 123–182 revascularizations in 1000
patients and gained 0.6–1.9 event-free months per
patient; SES also saved €1036–€1800 per patient: a larger
gain was achieved in those with multivessel disease and
in the 5-year horizon, provided that the SES efﬁcacy was
constant over time. In diabetics the SES averted 15%
more revascularizations and increased savings by 12%.
In single vessel disease the breakeven point of SES efﬁ-
cacy was 72% and that of charge for stenting with SES
was €7242 (17% higher than baseline). Overall fore-
casted savings to the NHS would be €38.927.652 per
year, if SES replaced all the stents. CONCLUSIONS: SES
is cost saving in a DRG-based reimbursement NHS,
however, the uptake of SES can be supported through
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OBJECTIVES: A recent study in cardiac surgery showed
a decrease in infections and mortality in patients receiv-
ing leukocyte-depleted erythrocytes (LD) compared 
to buffy-coat depleted packed red blood cells (PC).
However, cost-effectiveness data on leukoreduction of red
blood cell concentrates is scarce. We estimated cost-
effectiveness of LD over PC from a clinical trial involv-
ing valve and CABG surgery patients, from the hospital
perspective. METHODS: From May 1999 to May 2001,
in two university hospitals (Amsterdam and Leiden,
Netherlands), 496 adult patients undergoing cardiac
valve surgery (±CABG) were randomised double-blind
into two groups (LD or PC). The rates of in-hospital mor-
tality and mortality within 90 days after surgery were
primary endpoints. Cost-effectiveness in net costs per 
life-year gained (LYG) was established using standard
pharmaco-economic methods. RESULTS: In-hospital
mortality was 10.1% and 5.5% for PC and LD respec-
tively (OR 0.99–4.00; p = 0.05). Mortality in 90 days was
12.7% and 8.4% for PC and LD respectively (OR
0.84–2.73; p = 0.16). Average costs of ICU-care, standard
care, antibiotics and blood product utilisation were
€11,863.07 and €10,914.02 for PC and LD respectively.
Relative to PC, LD yields an estimated 2.15 un-
discounted LYG (0.70y at 3%, 0.21y at 5%). Ergo, net
costs are lower for LD and health outcomes better. CON-
CLUSIONS: From this clinical trial involving cardiac
surgery patients undergoing valve surgery with or
without CABG, leukodepleting red blood cell concen-
trates appears to be a dominant strategy in this prelimi-
nary evaluation.
